Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


People In Brief

This article was originally published in The Gray Sheet

Executive Summary

FDA chief information officer

You may also be interested in...

Senate Panel Approves FDA Appropriations, With Strong Words On Agency IT Systems

The Senate Appropriations Committee approves a $3.9 billion budget for the agency in fiscal 2013, including $319 million in federal funding for device activities.

VaxGen/diaDexus merger

Diagnostics firm diaDexus will merge with vaccine developer VaxGen in a stock-swap deal worth about $21.7 million, the firms announce April 14. Publicly held VaxGen will trade 51.6 million of its shares (which closed at $0.42 each just prior to the deal's announcement) for all shares of privately held diaDexus. However, the merged entity will be 61% owned by current diaDexus shareholders and 39% owned by VaxGen stockholders. The combined company also will be named diaDexus and will be run by current diaDexus officers. The diaDexus PLAC test is the only FDA-cleared blood test for assessing risk for coronary heart disease and ischemic stroke. "The proposed merger provides an efficient path for providing capital to fund the growth of our commercial organization, to continue activities needed for broader reimbursement of our PLAC test, and to provide for potential expansion of our product portfolio," diaDexus CEO Patrick Plewman said. VaxGen had about $32 million in cash as of Dec. 31, the company notes. Both firms are based in South San Francisco. VaxGen's stockholders failed to approve a previously planned merger deal with drug maker Oxigene in February

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts